Protagonist Therapeutics, Inc.
PTGX
$103.88
$3.933.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 74.06M | 46.02M | 209.22M | 209.18M | 207.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.06M | 46.02M | 209.22M | 209.18M | 207.80M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 74.06M | 46.02M | 209.22M | 209.18M | 207.80M |
| SG&A Expenses | 46.39M | 44.85M | 42.37M | 41.40M | 40.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.53M | 204.14M | 190.21M | 185.20M | 180.58M |
| Operating Income | -142.47M | -158.13M | 19.01M | 23.98M | 27.22M |
| Income Before Tax | -115.38M | -129.31M | 48.07M | 53.78M | 57.09M |
| Income Tax Expenses | -664.00K | 838.00K | 2.16M | 1.74M | 894.00K |
| Earnings from Continuing Operations | -114.71 | -130.15 | 45.91 | 52.04 | 56.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.71M | -130.15M | 45.91M | 52.04M | 56.19M |
| EBIT | -142.47M | -158.13M | 19.01M | 23.98M | 27.22M |
| EBITDA | -141.02M | -156.85M | 20.03M | 24.87M | 28.05M |
| EPS Basic | -1.80 | -2.04 | 0.76 | 0.84 | 0.89 |
| Normalized Basic EPS | -1.13 | -1.27 | 0.50 | 0.54 | 0.57 |
| EPS Diluted | -1.82 | -2.06 | 0.63 | 0.71 | 0.76 |
| Normalized Diluted EPS | -1.13 | -1.27 | 0.42 | 0.46 | 0.48 |
| Average Basic Shares Outstanding | 256.40M | 254.28M | 252.58M | 250.57M | 248.37M |
| Average Diluted Shares Outstanding | 261.81M | 254.28M | 256.65M | 254.65M | 252.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |